Inositol — Research Evidence
The summary below was generated by an AI system (Claude) based on the studies listed. It is a synthesis tool, not a clinical opinion. Read individual studies for full context.
Inositol is a naturally occurring sugar alcohol that functions as a second messenger in cellular signaling — specifically through the phosphatidylinositol (PI) pathway and inositol trisphosphate (IP3) signaling. It plays roles in insulin signal transduction, serotonin and dopamine receptor function, and the regulation of FSH and LH in the hypothalamic-pituitary-ovarian axis. Myo-inositol is the most abundant naturally occurring stereoisomer, found in fruits, beans, and whole grains. D-chiro-inositol is produced from myo-inositol via an insulin-regulated epimerase reaction.
The strongest evidence for inositol supplementation is in polycystic ovary syndrome (PCOS). Multiple randomized controlled trials and at least one systematic review (Unfer et al., 2017) support myo-inositol (typically 4g/day) for improving insulin sensitivity (HOMA-IR), reducing elevated androgens, improving LH/FSH ratios, and restoring menstrual regularity in women with PCOS. The 40:1 myo-inositol to d-chiro-inositol ratio has been proposed as physiologically relevant based on the ratio found in ovarian follicular fluid. This evidence base is considered moderate in strength — more robust than most supplement categories, though still limited by trial size and heterogeneity.
Evidence for anxiety and panic disorder is based on a smaller literature and should be interpreted cautiously. A double-blind crossover RCT (Palatnik et al.) found that 18g/day of inositol reduced panic attack frequency to a comparable degree as fluvoxamine over one month, with fewer side effects. OCD evidence is present but less consistent. These findings are intriguing but have not been replicated in large trials. The doses involved (12-18g/day) are substantially higher than doses discussed for other uses (900mg for sleep), and the GI side effect profile at these doses is notable.
The lower-dose use of inositol (900mg before sleep) has been popularized in wellness contexts, including by researchers like Andrew Huberman. The evidence base for this specific application is limited, though inositol's role in serotonin receptor modulation provides a plausible mechanistic rationale. This should be considered a low-evidence application at present.
Safety profile across all uses is generally favorable at doses under 4g/day. At higher doses (12-18g/day), GI side effects including nausea, flatulence, and loose stools are common and dose-dependent. A significant caution exists for individuals with bipolar disorder: theoretical and case-report level evidence suggests high-dose inositol may precipitate manic episodes, possibly through its role in second messenger signaling. This is a meaningful clinical concern that warrants avoidance of high-dose inositol in bipolar patients without psychiatric guidance. Use during pregnancy should be discussed with a qualified healthcare provider.
Key findings
- ✓Strongest evidence is in PCOS: myo-inositol (4g/day) has RCT support for improving insulin sensitivity, hormonal profiles, and menstrual regularity.
- ✓The 40:1 myo-inositol to d-chiro-inositol ratio reflects ovarian physiology and may be the most effective formulation for PCOS.
- ✓High-dose inositol (18g/day) showed comparable efficacy to fluvoxamine for panic disorder in a small crossover RCT, though this evidence has not been replicated at scale.
- ✓Evidence for OCD is present but less consistent than panic disorder findings.
- ✓Low-dose inositol (900mg) for sleep is mechanistically plausible but lacks direct RCT support at that specific dose.
Evidence gaps
- ?Large-scale, well-powered RCTs for anxiety and panic disorder are lacking; existing trials have small sample sizes.
- ?Long-term safety data (beyond 6 months) is limited across all indications.
- ?Head-to-head comparison of inositol forms (myo alone vs. 40:1 combination) across metabolic outcomes needs more study.
- ?Male populations are underrepresented; most metabolic and hormonal studies focus on women with PCOS.
- ?Mechanism behind bipolar risk at high doses is theoretical; prospective safety data is absent.
Safety summary
Generally well-tolerated at doses up to 4g/day. GI side effects (nausea, flatulence, loose stools) are common at high doses (12-18g/day) and are dose-dependent. High-dose inositol should be avoided in individuals with bipolar disorder due to theoretical risk of triggering mania. Pregnancy and breastfeeding: some evidence that inositol may be beneficial in gestational diabetes, but use during pregnancy should be discussed with a healthcare provider. No established Tolerable Upper Intake Level (UL) from regulatory bodies, but caution above 12g/day is advisable without medical supervision.
Studies (3)
Effects of Myo-inositol in Women with PCOS: A Systematic Review of Randomized Controlled Trials
Myo-inositol supplementation significantly improved hormonal profiles, insulin sensitivity, and menstrual regularity in women with PCOS. The 40:1 myo-inositol to d-chiro-inositol ratio was identified as physiologically relevant.
May improve hormonal balance, insulin sensitivity, and menstrual regularity in women with PCOS
Generally well-tolerated; mild GI upset (nausea, diarrhea) at doses above 4g/day
Heterogeneity across included trials; variable dosing protocols; most trials relatively short-duration (3-6 months)
Myo-Inositol and D-Chiro-Inositol in Improving Insulin Resistance in Women with Metabolic Syndrome
Myo-inositol supplementation (4g/day) was associated with improvements in fasting glucose, HOMA-IR, and triglycerides compared to placebo in women with metabolic syndrome over 6 months.
May support improvements in metabolic markers in women with metabolic syndrome
No serious adverse events reported; mild GI symptoms in a minority of participants
Small sample size; women only; metabolic syndrome is a heterogeneous condition; results may not generalize broadly
High-Dose Inositol in the Treatment of Panic Disorder and Obsessive-Compulsive Disorder
Inositol at 18g/day reduced panic attack frequency and severity in a double-blind crossover trial versus fluvoxamine, with comparable efficacy and fewer side effects over 1 month. Effects on OCD were more modest and less consistent.
High-dose inositol (12-18g/day) may reduce panic attack frequency; evidence for OCD is less consistent
High doses (>12g/day) commonly cause nausea, flatulence, and loose stools; these are dose-dependent and often transient
Small sample size; short duration (1 month); crossover design; evidence base relies on a small number of trials; has not been replicated at scale